Literature DB >> 29238853

Detection and genotyping of HPV in urine samples from Chilean women attending primary health care centers.

Nicolás Vergara1,2, Monserrat Balanda1, Wilma Hidalgo3, Héctor San Martín1, Alexis Aceituno4,5, Francisco Roldán1,3, Tania Villalón1, Melissa Hott1, Gloria Espinoza2, Andrea Quiero2, María T Valenzuela6, Eugenio Ramírez7.   

Abstract

Cervical cancer is the second most common malignant neoplasm in women worldwide representing approximately 10% of all types of cancers. Triage of women through cervical cytology has been an important strategy for the surveillance and control of new cases of cervical cancer. However, in many regions around the world cervical cytology has a low coverage compared to developed countries. The molecular detection of HPV is the most effective method to increase the screening sensitivity of women at risk of developing cervical cancer. There are very few studies about the efficacy of urine testing for detection of HPV in women followed up in primary health care centers. Consequently, the efficacy of using urine HPV screening in these populations has not been addressed yet. Here, we compared the detection of HPV in simultaneous urine and cervical samples of women followed up in primary health care centers. Urine and cervical samples were analyzed in 543 women attending at primary health care centers. HPV was detected by real time PCR, and HPV typing performed by PCR-RLB. A general HPV concordance of 86.2% (κ = 0.72) was determined between urine and cervical samples. The concordance for HPV-16 and 18 was almost perfect (κ = 0.82) and strong (κ = 0.77), respectively. The sensitivity and specificity for all HPV genotypes in urine using cervical samples as reference were 82.1 and 93.7%, respectively. The results showed that urine is a good alternative as clinical sample for HPV screening in women attending primary health care centers. Therefore, urine should be used as an alternative sample for increasing triage coverage either in refractory women participating in Pap surveillance programs or when cervical samples are not available.

Entities:  

Keywords:  Cervical samples; Chilean women; Human papillomavirus; Urine samples

Mesh:

Year:  2017        PMID: 29238853     DOI: 10.1007/s00430-017-0530-1

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  39 in total

1.  Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  P A Montanheiro; P A Montanheito; A C Penalva de Oliveira; M P Posada-Vergara; A C Milagres; C Tauil; P E Marchiori; A J S Duarte; J Casseb
Journal:  Braz J Med Biol Res       Date:  2005-10-26       Impact factor: 2.590

Review 2.  Detection of human papillomavirus DNA in urine. A review of the literature.

Authors:  A Vorsters; I Micalessi; J Bilcke; M Ieven; J Bogers; P Van Damme
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-05       Impact factor: 3.267

3.  Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test.

Authors:  Katrin Christine Asciutto; Anna J Henningsson; Henrik Borgfeldt; Lotten Darlin; Christer Borgfeldt
Journal:  Anticancer Res       Date:  2017-08       Impact factor: 2.480

4.  Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia.

Authors:  Chandrika J Piyathilake; Suguna Badiga; Michelle M Chambers; Ilene K Brill; Roland Matthews; Edward E Partridge
Journal:  Cancer       Date:  2016-05-31       Impact factor: 6.860

5.  Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia.

Authors:  Alba Lucía Cómbita; Tarik Gheit; Paula González; Devi Puerto; Raúl Hernando Murillo; Luisa Montoya; Alex Vorsters; Severien Van Keer; Pierre Van Damme; Massimo Tommasino; Gustavo Hernández-Suárez; Laura Sánchez; Rolando Herrero; Carolina Wiesner
Journal:  Cancer Prev Res (Phila)       Date:  2016-07-14

6.  Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples.

Authors:  François Coutlée; Patti Gravitt; Janet Kornegay; Catherine Hankins; Harriet Richardson; Normand Lapointe; Hélène Voyer; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 7.  Cervical cancer screening programs and guidelines in low- and middle-income countries.

Authors:  Brody Olson; Beth Gribble; Jasmyni Dias; Cassie Curryer; Kha Vo; Paul Kowal; Julie Byles
Journal:  Int J Gynaecol Obstet       Date:  2016-05-26       Impact factor: 3.561

Review 8.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-12-30       Impact factor: 3.641

Review 9.  The biology and life-cycle of human papillomaviruses.

Authors:  John Doorbar; Wim Quint; Lawrence Banks; Ignacio G Bravo; Mark Stoler; Tom R Broker; Margaret A Stanley
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

10.  Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Authors:  Grazyna Stanczuk; Gwendoline Baxter; Heather Currie; James Lawrence; Kate Cuschieri; Allan Wilson; Marc Arbyn
Journal:  BMJ Open       Date:  2016-04-25       Impact factor: 2.692

View more
  3 in total

1.  Human papillomavirus testing and cytology using physician-collected uterine cervical samples vs. self-collected vaginal samples and urine samples.

Authors:  Noriko Terada; Motoki Matsuura; Shoko Kurokawa; Yoko Nishimura; Masato Tamate; Kyoko Isoyama; Satoko Yamazaki; Hiroshi Shimada; Masahiro Suzuki; Yuta Tabuchi; Mizue Teramoto; Tsuyoshi Saito
Journal:  Int J Clin Oncol       Date:  2022-09-11       Impact factor: 3.850

2.  The simultaneous detection of the squamous cell carcinoma antigen and cancer antigen 125 in the cervical cancer serum using nano-Ag polydopamine nanospheres in an SERS-based lateral flow immunoassay.

Authors:  Ji Xia; Yifan Liu; Menglin Ran; Wenbo Lu; Liyan Bi; Qian Wang; Dan Lu; Xiaowei Cao
Journal:  RSC Adv       Date:  2020-08-06       Impact factor: 4.036

Review 3.  Diagnostic Test Accuracy of First-Void Urine Human Papillomaviruses for Presence Cervical HPV in Women: Systematic Review and Meta-Analysis.

Authors:  Peter Bober; Peter Firment; Ján Sabo
Journal:  Int J Environ Res Public Health       Date:  2021-12-17       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.